Caplin Point Laboratories Ltd
₹2297.10
-41.10 (1.76%)
Fri, 23 Oct 2026, 04:46 am
Health Technology
Pharmaceuticals: Major
24.5KCaplin Point Laboratories Ratios
| Particulars | 2007 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 9.29 | 15.70 | 6.01 | 6.32 | 5.37 | 4.87 | 5.08 | 12.94 | 25.06 | 30.68 | 30.06 | 17.32 | 10.01 | 12.73 | 17.32 | 12.13 | 21.99 | 28.51 |
| Price to book ratio | 0.96 | 0.50 | 0.56 | 0.83 | 1.16 | 1.16 | 1.65 | 5.42 | 11.92 | 13.05 | 11.91 | 4.81 | 2.25 | 2.58 | 3.47 | 2.41 | 4.32 | 5.48 |
| Price to sales ratio | 0.36 | 0.25 | 0.23 | 0.36 | 0.43 | 0.37 | 0.58 | 1.98 | 4.95 | 7.52 | 8.28 | 4.83 | 2.55 | 2.94 | 4.11 | 3.14 | 5.99 | 7.96 |
| Price to cash flow ratio | 6.67 | 15.26 | 1.07 | 32.35 | 2.34 | 1.33 | 2.11 | 5.85 | 34.26 | 40.03 | 60.64 | 36.09 | 44.24 | 11.10 | 14.60 | 15.35 | 27.82 | 31.62 |
| Enterprise value | 16.64Cr | 13.23Cr | 5.02Cr | 16.84Cr | 22.02Cr | 14.12Cr | 58.97Cr | 311Cr | 1462Cr | 2838Cr | 4269Cr | 2836Cr | 1916Cr | 2650Cr | 4706Cr | 3945Cr | 9295Cr | 14502Cr |
| Enterprise value to EBITDA ratio | 5.30 | 6.59 | 1.60 | 6.93 | 3.57 | 1.12 | 2.87 | 8.86 | 18.31 | 24.91 | 23.57 | 13.12 | 7.90 | 8.26 | 11.96 | 9.09 | 17.19 | 22.62 |
| Debt to equity ratio | 0.49 | 0.51 | 0.36 | 0.41 | 0.33 | 0.21 | 0.11 | 0.05 | 0.02 | 0 | 0 | 0 | 0.04 | 0.02 | 0 | 0 | 0 | 0 |
| Return on equity % | 0 | 0 | 9.78 | 13.52 | 23.05 | 25.57 | 36.46 | 49.29 | 64.23 | 54.19 | 49.25 | 35.43 | 27.20 | 22.71 | 22.46 | 22.37 | 21.79 | 20.76 |
Caplin Point Laboratories Ltd Ratios
The Caplin Point Laboratories Ltd Ratios page provides a complete fundamental analysis of Caplin Point Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Caplin Point Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Caplin Point Laboratories Ltd (NSE: CAPLIPOINT, BSE: 524742) is currently trading at ₹2297.10, with a market capitalization of ₹17940.66Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Caplin Point Laboratories Ltd remains a key stock for fundamental analysis using Caplin Point Laboratories Ltd Ratios.
Caplin Point Laboratories Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Caplin Point Laboratories Ltd P/E ratio currently stands at 28.51, making it one of the most tracked metrics in Caplin Point Laboratories Ltd Ratios.
Historically, the Caplin Point Laboratories Ltd P/E ratio has shown strong fluctuations:
- 2025: 28.51
- 2024: 21.99
- 2023: 12.13
- 2022: 17.32
- 2021: 12.73
The rising Caplin Point Laboratories Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Caplin Point Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 5.48.
Historical P/B trend:
- 2025: 5.48
- 2024: 4.32
- 2023: 2.41
- 2022: 3.47
Caplin Point Laboratories Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Caplin Point Laboratories Ltd P/S ratio currently stands at 7.96, an important part of Caplin Point Laboratories Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2025: 7.96
- 2024: 5.99
- 2023: 3.14
- 2022: 4.11
The rising Caplin Point Laboratories Ltd P/S ratio indicates improved revenue valuation by investors.
Caplin Point Laboratories Ltd Price to Cash Flow Ratio (P/CF)
The Caplin Point Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 31.62.
Historical Caplin Point Laboratories Ltd Price to Cash Flow Ratio:
- 2025: 31.62
- 2024: 27.82
- 2023: 15.35
- 2022: 14.60
- 2021: 11.10
The rising Caplin Point Laboratories Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Caplin Point Laboratories Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Caplin Point Laboratories Ltd EV currently stands at ₹14502Cr, representing the total company valuation including debt.
Historical EV trend:
- 2025: 14502Cr
- 2024: 9295Cr
- 2023: 3945Cr
- 2022: 4706Cr
Caplin Point Laboratories Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Caplin Point Laboratories Ltd EV/EBITDA ratio is currently 22.62, a key metric in Caplin Point Laboratories Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2025: 22.62
- 2024: 17.19
- 2023: 9.09
- 2022: 11.96
Higher Caplin Point Laboratories Ltd EV/EBITDA suggests premium valuation.
Caplin Point Laboratories Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Caplin Point Laboratories Ltd D/E ratio is currently 0, reflecting leverage and financial stability.
Historical D/E:
- 2025: 0
- 2024: 0
- 2023: 0
- 2022: 0
Caplin Point Laboratories Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Caplin Point Laboratories Ltd ROE currently stands at 20.76%, showing profitability and capital efficiency.
Historical ROE:
- 2025: 20.76
- 2024: 21.79
- 2023: 22.37
- 2022: 22.46
Caplin Point Laboratories Ltd demonstrates strong profitability and efficient capital utilization.
Caplin Point Laboratories Ltd Ratios Analysis Summary
The Caplin Point Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Caplin Point Laboratories Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Caplin Point Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
